BioMed X unveiled its new immunology discovery platform designed to allow for the accurate and fast identification of target antigens of human T cell receptors (TCRs). The platform is expected to be deployed via a collaborative model with pharmaceutical and biotechnology companies worldwide for preclinical research, vaccine development, and the development of new therapeutic concepts for treating autoimmune diseases and cancer. The underlying technology was the result of a collaboration be...